Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent BiologicsSTU:6IB -6.27%80 PS Ratio is 10.65 as of Jul. 20, 2026, which is 17% below its 10-year median of 12.88. GuruFocus rates STU:6IB with a GF Score™ of 80/100 and a GF Value™ of €11.19 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 930 Biotechnology companies, Innovent Biologics ranks worse than 54.3% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Innovent Biologics's share price is €9.692.
Innovent Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.91. Hence, Innovent Biologics's PS Ratio for today is 10.65.
The historical rank and industry rank for Innovent Biologics's PS Ratio or its related term are showing as below:
STU:6IB'
s PS Ratio Range Over the Past 10 Years
Min: 5.09 Med: 12.88 Max: 1115
Current: 10.75
During the past 10 years, Innovent Biologics's highest PS Ratio was 1115.00. The lowest was 5.09. And the median was 12.88.
STU:6IB's PS Ratio is ranked worse than 54.3% of 930
companies
in the Biotechnology industry
Industry Median: 9.35
vs STU:6IB: 10.75
During the past 12 months, the average Revenue per Share Growth Rate of Innovent Biologics was 34.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 34.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 20.10% per year.
During the past 10 years, Innovent Biologics's highest 3-Year average Revenue per Share Growth Rate was 451.70% per year. The lowest was 9.00% per year. And the median was 42.85% per year.
Back to Basics: PS Ratio
Innovent Biologics (STU:6IB) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Innovent Biologics PS Ratio Related Terms
Innovent Biologics PS Ratio Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Innovent Biologics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Innovent Biologics's Share Price of today is €9.692.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Innovent Biologics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Innovent Biologics (STU:6IB) has a PS Ratio of 10.65 as of Jul. 20, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Innovent Biologics and its competitors. This is 17% below median its historical median of 12.88. Over the past decade, Innovent Biologics' PS Ratio has ranged from 5.09 to 1,115.00. According to the industry distribution chart, Innovent Biologics ranks #505 out of 930 companies in the Biotechnology industry, placing it in the top 54.3%.
Is Innovent Biologics' PS Ratio too high?
Innovent Biologics' current PS Ratio of 10.65 is 17% below median its 10-year median of 12.88. Over the past 10 years, this metric has ranged from a low of 5.09 to a high of 1,115.00. The Biotechnology industry median PS Ratio is 9.35. Innovent Biologics' value of 10.65 is 13.9% above this industry median. Based on the distribution chart, Innovent Biologics ranks #505 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Innovent Biologics ranks #505 out of 930 companies for PS Ratio. This places Innovent Biologics in the lower half of its industry. The industry median PS Ratio is 9.35. Innovent Biologics' value of 10.65 is 13.9% above this benchmark. Historically, Innovent Biologics' own PS Ratio has ranged from 5.09 to 1,115.00 over the past decade. While the company's 10-year median is 12.88 vs. the industry median of 9.35, Innovent Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.35, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current PS Ratio of 10.65 is 13.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current PS Ratio is 10.65, which is 17% below median its own 10-year median of 12.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Modestly Undervalued. The stock's GF Value™ is €11.19, compared to a current price of €9.69 — trading 13.4% below its estimated fair value. The current PS Ratio is 10.65, which is 17% below median its 10-year median of 12.88 and 13.9% above the Biotechnology industry median of 9.35. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current PS Ratio is 10.65 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €9.69 is trading 13.4% below its estimated GF Value™ of €11.19.
GuruFocus considers Innovent Biologics to be Modestly Undervalued.
Key valuation signals for STU:6IB:
PS Ratio: 10.65 (17% below median its 10-year median of 12.88)
GF Value™: €11.19 vs. price of €9.69 (13.4% below fair value)
Industry Position: 13.9% above the Biotechnology median (#505 of 930)
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
